{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T02:11:30Z","timestamp":1787969490119,"version":"build-2784847793"},"reference-count":14,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2022-00801"],"award-info":[{"award-number":["2022-00801"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016669","name":"Sj\u00f6bergstiftelsen","doi-asserted-by":"publisher","award":["2023-01-03:3"],"award-info":[{"award-number":["2023-01-03:3"]}],"id":[{"id":"10.13039\/100016669","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["CAN 222167Pj"],"award-info":[{"award-number":["CAN 222167Pj"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.annonc.2024.01.004","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T03:06:54Z","timestamp":1708484814000},"page":"245-247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hit hard and remove treatment \u2013 this treatment strategy in Hodgkin Lymphoma promises less fatigue and less sick-leave"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6158-3041","authenticated-orcid":false,"given":"I.","family":"Glimelius","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.annonc.2024.01.004_bib1","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.annonc.2023.11.014","article-title":"Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced stage Hodgkin Lymphoma: results from the randomized international GHSG HD18 trial","volume":"35","author":"Ferdinandus","year":"2024","journal-title":"Ann Oncol"},{"issue":"10114","key":"10.1016\/j.annonc.2024.01.004_bib2","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","volume":"390","author":"Borchmann","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.annonc.2024.01.004_bib3","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s11764-015-0436-0","article-title":"Sick leave and disability pension in Hodgkin lymphoma survivors by stage, treatment, and follow-up time-a population-based comparative study","volume":"9","author":"Glimelius","year":"2015","journal-title":"J\u00a0Cancer Surviv"},{"issue":"1","key":"10.1016\/j.annonc.2024.01.004_bib4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41572-020-0189-6","article-title":"Hodgkin lymphoma","volume":"6","author":"Connors","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.annonc.2024.01.004_bib5","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1182\/blood-2021-152497","article-title":"Classical Hodgkin Lymphoma; Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT): physician First-Line Treatment Preferences for Stage III or IV Classical Hodgkin Lymphoma","volume":"138","author":"Evens","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2024.01.004_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.18.00015","article-title":"Patient-Reported Survivorship Care Practices and Late Effects After Treatment of Hodgkin and Non-Hodgkin Lymphoma","volume":"2","author":"Frick","year":"2018","journal-title":"JCO Clin Cancer Inform"},{"issue":"11","key":"10.1016\/j.annonc.2024.01.004_bib7","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2022.07.1941","article-title":"ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe","volume":"33","author":"Vaz-Luis","year":"2022","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2024.01.004_bib8","doi-asserted-by":"crossref","first-page":"4918","DOI":"10.1002\/cam4.2363","article-title":"Distribution of hospital care among pediatric and young adult Hodgkin lymphoma survivors-A population-based cohort study from Sweden and Denmark","volume":"8","author":"Glimelius","year":"2019","journal-title":"Cancer Med"},{"issue":"13","key":"10.1016\/j.annonc.2024.01.004_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13133135","article-title":"The Impact of Healthy Lifestyles on Late Sequelae in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors. A Systematic Review by the Fondazione Italiana Linfomi","volume":"13","author":"Minoia","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.annonc.2024.01.004_bib10","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1007\/s10880-023-09944-6","article-title":"Web-Based Cognitive-Behavioral Therapy to Reduce Severe\u00a0Cancer-Related Fatigue Among Survivors of Hodgkin Lymphoma: A Feasibility Study","volume":"30","author":"Esser","year":"2023","journal-title":"J\u00a0Clin Psychol Med Settings"},{"issue":"12","key":"10.1016\/j.annonc.2024.01.004_bib11","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/ajh.24184","article-title":"Long-term survival in young and middle-aged Hodgkin lymphoma patients in Sweden 1992-2009-trends in cure proportions by clinical characteristics","volume":"90","author":"Glimelius","year":"2015","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.annonc.2024.01.004_bib12","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/ajh.24623","article-title":"Increased healthcare use up to 10 years among relapse-free Hodgkin lymphoma survivors in the era of intensified chemotherapy and limited radiotherapy","volume":"92","author":"Glimelius","year":"2017","journal-title":"Am J Hematol"},{"issue":"13","key":"10.1016\/j.annonc.2024.01.004_bib13","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1080\/10428194.2019.1613538","article-title":"Socioeconomic impact of Hodgkin lymphoma in adult patients: a systematic literature review","volume":"60","author":"Palmarsdottir","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.annonc.2024.01.004_bib14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bjh.18199","article-title":"Late relapses in Hodgkin lymphoma - should we search for the needle in the haystack?","volume":"198","author":"El-Galaly","year":"2022","journal-title":"Br J Haematol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753424000115?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753424000115?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T07:02:56Z","timestamp":1760338976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753424000115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0923753424000115"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2024.01.004","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hit hard and remove treatment \u2013 this treatment strategy in Hodgkin Lymphoma promises less fatigue and less sick-leave","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2024.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Society for Medical Oncology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}